Quantitative hydrophilic interaction chromatography-mass spectrometry analysis of N-acetylneuraminic acid and N-acetylmannosamine in human plasma

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 1000, Issue , 2015, Pages 105-111

  Shi, Yifan ^a   Xu, Xin ^b   Fang, Meng ^a   Zhang, Michael ^a   Li, Yinghe ^a   Gillespie, Brad ^c   Yorke, Selwyn ^d   Yang, Nora ^b   McKew, John C ^b   Gahl, William A ^e   Huizing, Marjan ^e   Carrillo Carrasco, Nuria ^b   Wang, Amy Qiu ^b  

^a Alliance Pharma Inc   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^d New Zealand Pharmaceuticals Limited   (New Zealand)

^e NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

HILIC; LC MS MS; N acetylmannosamine; N acetylneuraminic acid; Phospholipid removal; Validation

Indexed keywords

BODY FLUIDS; CARBOXYLIC ACIDS; HYDROPHILICITY; LIQUID CHROMATOGRAPHY; MAMMALS; MASS SPECTROMETRY; PHOSPHOLIPIDS; PLASMA (HUMAN); QUALITY CONTROL; SPECTROMETRY;

CHROMATOGRAPHIC SEPARATIONS; HILIC; HYDROPHILIC INTERACTION CHROMATOGRAPHY; LC-MS/MS; LOWER LIMIT OF QUANTITATIONS; N-ACETYLNEURAMINIC ACID; SELECTIVE LIQUID CHROMATOGRAPHY; VALIDATION;

CHROMATOGRAPHY;

BIOLOGICAL MARKER; BOVINE SERUM ALBUMIN; N ACETYLMANNOSAMINE; N ACETYLNEURAMINIC ACID; PHOSPHOLIPID; UNCLASSIFIED DRUG; HEXOSAMINE; N-ACETYLMANNOSAMINE;

ARTICLE; CALIBRATION; CONTROLLED STUDY; EXTRACTION; HUMAN; HYDROPHILIC INTERACTION CHROMATOGRAPHY; LIMIT OF QUANTITATION; PLASMA; PRIORITY JOURNAL; PROTEIN STABILITY; QUALITY CONTROL; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; BLOOD; CHEMICAL PHENOMENA; DRUG STABILITY; LIQUID CHROMATOGRAPHY; PROCEDURES;

BOVINAE; MAMMALIA;

CHROMATOGRAPHY, LIQUID; DRUG STABILITY; HEXOSAMINES; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; N-ACETYLNEURAMINIC ACID; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY;

EID: 84937925139     PISSN: 15700232     EISSN: 1873376X     Source Type: Journal    
DOI: 10.1016/j.jchromb.2015.07.018     Document Type: Article

References (41)

1. Comprehensive Glycoscience: from Chemistry to Systems Biology 2007, Elsevier Ltd., Oxford, UK. first ed. G.-J. Boons, J.P. Kamerling, Y.C. Lee, A. Suzuki, N. Taniguchi, A.G.J. Voragen (Eds.).
2. Varki A. Sialic acids in human health and disease. Trends Mol. Med. 2008, 14:351.
3. Schauer R. Sialic acids as regulators of molecular and cellular interactions. Curr. Opin. Struct. Biol. 2009, 19:507.
4. Nishino I., Carrillo-Carrasco N., Argov Z. GNE myopathy: current update and future therapy. J. Neurol. Neurosurg. Psychiatry 2015, 86:385.
5. Huizing M., Krasnewich D.M. Hereditary inclusion body myopathy: a decade of progress. Biochim. Biophys. Acta 2009, 1792:881.
6. Stasche R., Hinderlich S., Weise C., Effertz K., Lucka L., Moormann P., Reutter W. A bifunctional enzyme catalyzes the first two steps in N-acetylneuraminic acid biosynthesis of rat liver. Molecular cloning and functional expression of UDP-N-acetyl-glucosamine 2-epimerase/N-acetylmannosamine kinase. J. Biol. Chem. 1997, 272:24319.
7. Noguchi S., Keira Y., Murayama K., Ogawa M., Fujita M., Kawahara G., Oya Y., Imazawa M., Goto Y., Hayashi Y.K., Nonaka I., Nishino I. Reduction of UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase activity and sialylation in distal myopathy with rimmed vacuoles. J. Biol. Chem. 2004, 279:11402.
8. Gagiannis D., Orthmann A., Danssmann I., Schwarzkopf M., Weidemann W.W., Horstkorte R. Reduced sialylation status in UDP-N-acetylglucosamine-2-epimerase/N-acetylmannosamine kinase (GNE)-deficient mice. Glycoconj. J. 2007, 24:125.
9. Nishino I., Malicdan M.C., Murayama K., Nonaka I., Hayashi Y.K., Noguchi S. Molecular pathomechanism of distal myopathy with rimmed vacuoles. Acta Myol. 2005, 24:80.
10. Niethamer T.K., Yardeni T., Leoyklang P., Ciccone C., Astiz-Martinez A., Jacobs K., Dorward H.M., Zerfas P.M., Gahl W.A., Huizing M. Oral monosaccharide therapies to reverse renal and muscle hyposialylation in a mouse model of GNE myopathy. Mol. Genet. Metab. 2012, 107:748.
11. Yonekawa T., Malicdan M.C., Cho A., Hayashi Y.K., Nonaka I., Mine T., Yamamoto T., Nishino I., Noguchi S. Sialyllactose ameliorates myopathic phenotypes in symptomatic GNE myopathy model mice. Brain 2014, 137:2670.
12. Malicdan M.C., Noguchi S., Hayashi Y.K., Nonaka I., Nishino I. Prophylactic treatment with sialic acid metabolites precludes the development of the myopathic phenotype in the DMRV-hIBM mouse model. Nat. Med. 2009, 15:690.
13. Crook M. The determination of plasma or serum sialic acid. Clin. Biochem. 1993, 26:31.
14. Matsuno K., Suzuki S. Simple fluorimetric method for quantification of sialic acids in glycoproteins. Anal. Biochem. 2008, 375:53.
15. Teshima S., Tamai K., Hayashi Y., Emi S. New enzymatic determination of sialic acid in serum. Clin. Chem. 1988, 34:2291.
16. Haverkamp J., van Halbeek H., Dorland L., Vliegenthart J.F., Pfeil R., Schauer R. High-resolution 1H NMR spectroscopy of free and glycosidically linked O-acetylated sialic acids. Eur. J. Biochem. 1982, 122:305.
17. Stankovics J., Molnar D., Burus I., Pinter Z. Infantile sialic acid storage disease diagnosed by gas chromatography-mass spectroscopy analyses of urine sample. J. Inherit. Metab. Dis. 1997, 20:728.
18. Siskos P.A., Spyridaki M.H. Determination of sialic acids in biological fluids using reversed-phase ion-pair high-performance liquid chromatography. J. Chromatogr. B Biomed. Sci. Appl. 1999, 724:205.
19. Makatsori E., Fermani K., Aletras A., Karamanos N.K., Tsegenidis T. Screening of N-acylneuraminic acids in serum and tissue specimens of mouse C57BI with Lewis' lung cancer by high-performance liquid chromatography. J. Chromatogr. B Biomed. Sci. Appl. 1998, 712:23.
20. Galuska S.P., Geyer H., Weinhold B., Kontou M., Röhrich R.C., Bernard U., Gerardy-Schahn R., Reutter W., Münster-Kühnel A., Geyer R. Quantification of nucleotide-activated sialic acids by a combination of reduction and fluorescent labeling. Anal. Chem. 2010, 82:4591.
21. van der Ham M., Prinsen B.H., Huijmans J.G., Abeling N.G., Dorland B., Berger R., de Koning T.J., de Sain-van der Velden M.G. Quantification of free and total sialic acid excretion by LC-MS/MS. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2007, 848:251.
22. Tebani A., Schlemmer D., Imbard A., Rigal O., Porquet D., Benoist J.F. Measurement of free and total sialic acid by isotopic dilution liquid chromatography tandem mass spectrometry method. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2011, 879:3694.
23. Yasuno S., Kokubo K., Kamei M. New method for determining the sugar composition of glycoproteins, glycolipids, and oligosaccharides by high-performance liquid chromatography. Biosci. Biotechnol. Biochem. 1999, 63:1353.
24. Cummings J., Ward T.H., Dive C. Fit-for-purpose biomarker method validation in anticancer drug development. Drug Discov. Today 2010, 15:816.
25. Lee J.W., Devanarayan V., Barrett Y.C., Weiner R., Allinson J., Fountain S., Keller S., Weinryb I., Green M., Duan L., Rogers J.A., Millham R., O'Brien P.J., Sailstad J., Khan M., Ray C., Wagner J.A. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm. Res. 2006, 23:312.
26. Wang J., Lee J., Burns D., Doherty D., Brunner L., Peterson M., DeSilva B. Fit-for-purpose method validation and application of a biomarker (C-terminal telopeptides of type 1 collagen) in denosumab clinical studies. AAPS J. 2009, 11:385.
27. Jian W., Edom R.W., Weng N. Important considerations for quantitation of small-molecule biomarkers using LC-MS. Bioanalysis 2012, 4:2431.
28. Houghton R., Horro Pita C., Ward I., Macarthur R. Generic approach to validation of small-molecule LC-MS/MS biomarker assays. Bioanalysis 2009, 1:1365.
29. Jian W., Edom R.W., Weng N. Recent advances in application of hydrophilic interaction chromatography for quantitative bioanalysis. J. Sep. Sci. 2010, 33:681.
30. Jian W., Xu Y., Edom R.W., Weng N. Analysis of polar metabolites by hydrophilic interaction chromatography-MS/MS. Bioanalysis 2011, 3:899.
31. Shou W.Z., Weng N. Simple means to alleviate sensitivity loss by trifluoroacetic acid (TFA) mobile phases in the hydrophilic interaction chromatography-electrospray tandem mass spectrometric (HILIC-ESI/MS/MS) bioanalysis of basic compounds. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2005, 825:186.
32. Buhrman D.L., Price P.I., Rudewiczcor P.J. Quantitation of SR 27417 in human plasma using electrospray liquid chromatography-tandem mass spectrometry: a study of ion suppression. J. Am. Soc. Mass Spectrom. 1996, 7:1099.
33. Jemal M., Xia Y.Q. LC-MS Development strategies for quantitative bioanalysis. Curr. Drug Metab. 2006, 7:491.
34. Liu G., Ji Q.C., Arnold M.E. Identifying, evaluating, and controlling bioanalytical risks resulting from nonuniform matrix ion suppression/enhancement and nonlinear liquid chromatography-mass spectrometry assay response. Anal. Chem. 2010, 82:9671.
35. Wang S., Cyronak M., Yang E. Does a stable isotopically labeled internal standard always correct analyte response? A matrix effect study on a LC/MS/MS method for the determination of carvedilol enantiomers in human plasma. J. Pharm. Biomed. Anal. 2007, 43:701.
36. Cote C., Bergeron A., Mess J.N., Furtado M., Garofolo F. Matrix effect elimination during LC-MS/MS bioanalytical method development. Bioanalysis 2009, 1:1243.
37. Chambers E., Wagrowski-Diehl D.M., Lu Z., Mazzeo J.R. Systematic and comprehensive strategy for reducing matrix effects in LC/MS/MS analyses. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2007, 852:22.
38. Liu G., Snapp H.M., Ji Q.C., Arnold M.E. Strategy of accelerated method development for high-throughput bioanalytical assays using ultra high-performance liquid chromatography coupled with mass spectrometry. Anal. Chem. 2009, 81:9225.
39. Lahaie M., Mess J.N., Furtado M., Garofolo F. Elimination of LC-MS/MS matrix effect due to phospholipids using specific solid-phase extraction elution conditions. Bioanalysis 2010, 2:1011.
40. Sancho J.V., Pozo O.J., López F.J., Hernández F. Different quantitation approaches for xenobiotics in human urine samples by liquid chromatography/electrospray tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2002, 16:639.
41. Ji Q.C., Rodila R., Gage E.M., El-Shourbagy T.A. A strategy of plasma protein quantitation by selective reaction monitoring of an intact protein. Anal. Chem. 2003, 75:7008.